The market opportunities for Apomorphine hydrochloride lie in its diverse applications, geographical expansion, and evolving manufacturing methods. The exploration of patents and regional ...

Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New ...

Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced ...

As of Friday, January 09, Aquestive Therapeutics, Inc.’s AQST share price has dipped by 37.28%, which has investors ...

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...

Digital Silk, a digital agency focused on branding, custom web design, and digital marketing, has analyzed 58 publicly available generative AI statistics to examine adoption patterns, workforce demand ...

The first sublingual therapy for the intermittent treatment of uncontrolled OFF episodes for adult people living with Parkinson’s Disease ...

Parkinson's disease is on the rise, with U.S. diagnoses expected to reach 1.2 million by 2030. As the most common movement disorder and second most common neurodegenerative disorder, Parkinson's ...

Supernus Pharmaceuticals is acquiring Sage Therapeutics for $8.5/share plus up to $3.5/share in CVRs tied to Zurzuvae sales milestones. The deal diversifies Supernus' CNS portfolio, offsets revenue ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...